Literature DB >> 32546423

Insufficient future liver remnant and preoperative cholangitis predict perioperative outcome in perihilar cholangiocarcinoma.

Jan Bednarsch1, Zoltan Czigany1, Isabella Lurje2, Iakovos Amygdalos1, Pavel Strnad3, Paul Halm1, Georg Wiltberger1, Tom F Ulmer1, Maximilian Schulze-Hagen4, Philipp Bruners4, Ulf P Neumann5, Georg Lurje6.   

Abstract

BACKGROUND: Major liver resection has evolved as the mainstay of treatment for patients with perihilar cholangiocarcinoma (pCCA). Here we assessed the suitability of preoperative future liver remnant (FLR) measurement to predict perioperative complications, since surgical morbidity and mortality are high compared to other malignancies.
METHODS: Between 2011 and 2016, 91 patients with pCCA underwent surgery in curative intent at our institution. The associations of surgical complications with FLR and clinico-pathological characteristics were assessed using logistic regression analyses. Different methods of FLR assessment, the calculated-FLR (cFLR; ratio of FLR to total liver volume), standardized FLR (sFLR; ratio of FLR to liver volume estimated by body surface area) and FLR to bodyweight ratio (FLR/BW) were tested for validity.
RESULTS: Multivariable analysis identified preoperative cholangitis (Exp(B) = 0.236; p = 0.030) as the single significant predictor of postoperative mortality and cFLR (Exp(B) = 0.009, p = 0.004) as the single significant predictor of major postoperative morbidity (Clavien-Dindo ≥ 3b). Based on these findings we designed a futility criterion (cFLR<40% OR preoperative cholangitis) predicting in-house mortality.
CONCLUSIONS: In patients with pCCA, the preoperative FLR<40% as well as preoperative cholangitis are two risk factors to independently predict perioperative morbidity and mortality. The cFLR should be the preferred method of liver volumetry.
Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32546423     DOI: 10.1016/j.hpb.2020.04.017

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  5 in total

1.  Bacterial bile duct colonization in perihilar cholangiocarcinoma and its clinical significance.

Authors:  Jan Bednarsch; Zoltan Czigany; Lara Rosaline Heij; Tom Luedde; Ronald van Dam; Sven Arke Lang; Tom Florian Ulmer; Mathias Walter Hornef; Ulf Peter Neumann
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

Review 2.  Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.

Authors:  Sandra Pavicevic; Sophie Reichelt; Deniz Uluk; Isabella Lurje; Cornelius Engelmann; Dominik P Modest; Uwe Pelzer; Felix Krenzien; Nathanael Raschzok; Christian Benzing; Igor M Sauer; Sebastian Stintzing; Frank Tacke; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Georg Lurje
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

3.  The prognostic impact of preoperative body composition in perihilar and intrahepatic cholangiocarcinoma.

Authors:  Isabella Lurje; Zoltan Czigany; Sarah Eischet; Jan Bednarsch; Tom Florian Ulmer; Peter Isfort; Pavel Strnad; Christian Trautwein; Frank Tacke; Ulf Peter Neumann; Georg Lurje
Journal:  Hepatol Commun       Date:  2022-05-26

4.  Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma.

Authors:  Jan Bednarsch; Jakob Kather; Xiuxiang Tan; Shivan Sivakumar; Claudio Cacchi; Georg Wiltberger; Zoltan Czigany; Florian Ulmer; Ulf Peter Neumann; Lara Rosaline Heij
Journal:  Liver Cancer       Date:  2021-05-06       Impact factor: 11.740

Review 5.  The Value of Platelet-to-Lymphocyte Ratio as a Prognostic Marker in Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Dong Liu; Zoltan Czigany; Lara R Heij; Stefan A W Bouwense; Ronald van Dam; Sven A Lang; Tom F Ulmer; Ulf P Neumann; Jan Bednarsch
Journal:  Cancers (Basel)       Date:  2022-01-16       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.